Interferon-based treatment of chronic hepatitis C.
The treatment of patients with chronic hepatitis C has rapidly evolved in the past 10 years centered on the use of interferon alpha 2 as an antiviral and immunomodulatory agent against hepatitis C virus. Firstly used as a monotherapy associated with a deceiving long-term efficacy, interferon alpha was then combined with ribavirin, a nucleoside analog with large antiviral properties. Combination of both drugs dramatically improved the efficacy of treatment with 50% of patients reaching a sustained viral response, characterized by the final eradication of the virus from the infected individual. Surprisingly, this synergistic effect remains greatly unexplained. The third step consisted in the use of pegylated interferon in order to adapt its pharmacokinetics and to allow a better efficacy with a more tolerable dosing schedule: once weekly subcutaneous injection instead of thrice weekly. Pegylated interferon combined with ribavirin during 24-48 weeks of treatment is the current standard of care with nearly 60% of sustained virologic response, overall. Development of new forms of interferon alpha are on the way with promising preliminary results.
Souvignet
Claude
C
Hospices Civils de Lyon, Hôtel Dieu, Service d'Hépatologie et Gastroentérologie, 69002 Lyon, France.
Lejeune
Olivier
O
Trepo
Christian
C
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology; D002908:Chronic Disease / Q000628:therapy; D016174:Hepacivirus / Q000378:metabolism; D019698:Hepatitis C, Chronic / Q000628:therapy*; D006801:Humans; D007372:Interferons / Q000378:metabolism*; D008954:Models, Biological; D011092:Polyethylene Glycols / Q000737:chemistry* / Q000378:metabolism; D012254:Ribavirin / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
D000998:Antiviral Agents; D011092:Polyethylene Glycols; D012254:Ribavirin; D007372:Interferons